Thyroid Cancer – Pipeline Review, H1 2013

Published: June 2013
No. of Pages: 280
   

Summary

Global Markets Direct’s, ''Thyroid Cancer - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thyroid Cancer. Thyroid Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Thyroid Cancer.
  • A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Thyroid Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Thyroid Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Thyroid Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Thyroid Cancer – Pipeline Review, H1 2013

Table Of Contents

Table Of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Thyroid Cancer Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Thyroid Cancer 9
Thyroid Cancer Therapeutics under Development by Companies 11
Thyroid Cancer Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Thyroid Cancer Therapeutics – Products under Development by Companies 20
Thyroid Cancer Therapeutics – Products under Investigation by Universities/Institutes 24
Companies Involved in Thyroid Cancer Therapeutics Development 25
Bristol-Myers Squibb Company 25
F. Hoffmann-La Roche Ltd. 26
Biogen Idec Inc. 27
Sanofi-Aventis 28
AstraZeneca PLC 29
Daiichi Sankyo Company, Ltd 30
Merck & Co., Inc. 31
Emergent BioSolutions Inc. 32
Takeda Pharmaceutical Company Limited 33
Plexxikon Inc. 34
Reliance Life Sciences Pvt. Ltd. 35
Celltrion, Inc. 36
Bio-Path Holdings, Inc. 37
Novartis AG 38
Eisai Co., Ltd. 39
Genmab A/S 40
Sandoz Inc. 41
Exelixis, Inc. 42
Celgene Corporation 43
Bayer AG 44
EpiCept Corporation 45
IMMUNOMEDICS, INC 46
MethylGene Inc 47
Bionomics Limited 48
OXiGENE, Inc. 49
Accentia Biopharmaceuticals, Inc. 50
Pharmacyclics, Inc. 51
Cancer Research Technology Limited 52
Memgen, LLC. 53
Azaya Therapeutics, Inc. 54
Vascular Biogenics Ltd. 55
Globeimmune, Inc. 56
Biovista Inc. 57
AmpliMed Corporation 58
CureTech Ltd. 59
Genelux Corporation 60
Trophogen, Inc. 61
Thyroid Cancer – Therapeutics Assessment 62
Assessment by Monotherapy Products 62
Assessment by Route of Administration 63
Assessment by Molecule Type 65
Drug Profiles 68
lenvatinib - Drug Profile 68
motesanib diphosphate - Drug Profile 71
pasireotide - Drug Profile 75
obinutuzumab - Drug Profile 78
sorafenib tosylate - Drug Profile 80
vandetanib - Drug Profile 84
vandetanib - Drug Profile 90
mocetinostat - Drug Profile 96
ibrutinib - Drug Profile 99
abexinostat hydrochloride - Drug Profile 102
SAR-245409 - Drug Profile 104
panobinostat - Drug Profile 106
dasiprotimut T - Drug Profile 111
docetaxel liposomal - Drug Profile 113
vemurafenib - Drug Profile 115
cabozantinib - Drug Profile 118
cabozantinib - Drug Profile 120
ISF-35 - Drug Profile 122
imexon - Drug Profile 124
VB-111 - Drug Profile 126
BMS-936564 - Drug Profile 127
pidilizumab - Drug Profile 128
BP-100-1.02 - Drug Profile 130
TRX-201 - Drug Profile 131
Autologous Recombinant Idiotypic Vaccine - Drug Profile 132
GI-6207 - Drug Profile 133
epratuzumab - Drug Profile 134
PLX-3397 - Drug Profile 139
buparlisib - Drug Profile 141
lithium carbonate - Drug Profile 144
lenalidomide - Drug Profile 145
DI-Leu16-IL2 Immunocytokine - Drug Profile 148
ofatumumab - Drug Profile 149
fosbretabulin disodium - Drug Profile 153
rituximab - Drug Profile 157
ocaratuzumab - Drug Profile 160
rituximab biosimilar - Drug Profile 162
rituximab biosimilar - Drug Profile 164
ETD-5 - Drug Profile 165
ABT-199 - Drug Profile 166
rituximab biosimilar - Drug Profile 169
Thyroid Stimulating Hormone Analog - Drug Profile 170
rituximab biosimilar - Drug Profile 171
PLX-4720 - Drug Profile 172
131I-Rituximab - Drug Profile 173
Drug Adaptation Program - Drug Profile 174
EDC-1 - Drug Profile 175
Andrographolide - Drug Profile 177
interferon alfa-2b biosimilar - Drug Profile 178
Drug For Lung and Thyroid Cancer - Drug Profile 179
GLONC-2 - Drug Profile 180
BVA-501 - Drug Profile 181
BVA-701 - Drug Profile 182
ONC-301 - Drug Profile 183
DNA Fusion Vaccines - Drug Profile 184
Thyroid Cancer Therapeutics – Drug Profile Updates 186
Thyroid Cancer Therapeutics – Discontinued Products 262
Thyroid Cancer Therapeutics - Dormant Products 263
Thyroid Cancer – Product Development Milestones 265
Featured News & Press Releases 265
Appendix 275
Methodology 275
Coverage 275
Secondary Research 275
Primary Research 275
Expert Panel Validation 275
Contact Us 276
Disclaimer 276

List Of Tables

Number of Products Under Development for Thyroid Cancer, H1 2013 13
Products under Development for Thyroid Cancer – Comparative Analysis, H1 2013 14
Number of Products under Development by Companies, H1 2013 16
Number of Products under Development by Companies, H1 2013 (Contd..1) 17
Number of Products under Development by Companies, H1 2013 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2013 19
Comparative Analysis by Late Stage Development, H1 2013 20
Comparative Analysis by Mid Clinical Stage Development, H1 2013 21
Comparative Analysis by Early Clinical Stage Development, H1 2013 22
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 23
Products under Development by Companies, H1 2013 24
Products under Development by Companies, H1 2013 (Contd..1) 25
Products under Development by Companies, H1 2013 (Contd..2) 26
Products under Development by Companies, H1 2013 (Contd..3) 27
Products under Investigation by Universities/Institutes, H1 2013 28
Bristol-Myers Squibb Company, H1 2013 29
F. Hoffmann-La Roche Ltd., H1 2013 30
Biogen Idec Inc., H1 2013 31
Sanofi-Aventis, H1 2013 32
AstraZeneca PLC, H1 2013 33
Merck & Co., Inc., H1 2013 35
Takeda Pharmaceutical Company Limited, H1 2013 37
Plexxikon Inc., H1 2013 38
Reliance Life Sciences Pvt. Ltd., H1 2013 39
Celltrion, Inc., H1 2013 40
Bio-Path Holdings, Inc., H1 2013 41
Novartis AG, H1 2013 42
Eisai Co., Ltd., H1 2013 43
Genmab A/S, H1 2013 44
Sandoz Inc., H1 2013 45
Exelixis, Inc., H1 2013 46
Celgene Corporation, H1 2013 47
Bayer AG, H1 2013 48
IMMUNOMEDICS, INC, H1 2013 50
MethylGene Inc, H1 2013 51
Bionomics Limited, H1 2013 52
OXiGENE, Inc., H1 2013 53
Accentia Biopharmaceuticals, Inc., H1 2013 54
Pharmacyclics, Inc., H1 2013 55
Cancer Research Technology Limited, H1 2013 56
Memgen, LLC., H1 2013 57
Azaya Therapeutics, Inc., H1 2013 58
Vascular Biogenics Ltd., H1 2013 59
Globeimmune, Inc., H1 2013 60
Biovista Inc., H1 2013 61
AmpliMed Corporation, H1 2013 62
CureTech Ltd., H1 2013 63
Genelux Corporation, H1 2013 64
Trophogen, Inc., H1 2013 65
Assessment by Monotherapy Products, H1 2013 66
Assessment by Stage and Route of Administration, H1 2013 68
Assessment by Stage and Molecule Type, H1 2013 71
Thyroid Cancer Therapeutics – Drug Profile Updates 190
Thyroid Cancer Therapeutics – Discontinued Products 266
Thyroid Cancer Therapeutics – Dormant Products 267
Thyroid Cancer Therapeutics – Dormant Products (Contd..1) 268

List Of Figures

Number of Products under Development for Thyroid Cancer, H1 2013 13
Products under Development for Thyroid Cancer – Comparative Analysis, H1 2013 14
Products under Development by Companies, H1 2013 15
Products under Investigation by Universities/Institutes, H1 2013 19
Late Stage Products, H1 2013 20
Mid Clinical Stage Products, H1 2013 21
Early Clinical Stage Products, H1 2013 22
Discovery and Pre-Clinical Stage Products, H1 2013 23
Assessment by Monotherapy Products, H1 2013 66
Assessment by Route of Administration, H1 2013 67
Assessment by Stage and Route of Administration, H1 2013 68
Assessment by Molecule Type, H1 2013 69
Assessment by Stage and Molecule Type, H1 2013 70

Published By: Global Markets Direct
Product Code: Global Markets Direct6282


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 400,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

Live Chat
Live Chat by Comm100